Clinical and Molecular Studies in Families With Inherited Eye Disease

Plain-language summary

This study aims to examine, at the clinical and molecular (genetic) level, individuals and families affected by inherited eye diseases. People aged 4 and over who have a congenital, childhood, or age-related inherited eye disease, or who are family members of such individuals, could take part. It is a trial without an assigned phase and is currently recruiting.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Recruiting

Sponsor

National Eye Institute (NEI)

Start date

10/4/2016

Estimated completion

1/1/2032

Countries

United States, China, India, Italy, Pakistan, Philippines, Ukraine, United Kingdom

Related genes

Locations

• La Jolla, United States
• Bethesda, United States
• Durham, United States
• Guangzhou, China
• Madurai, India
• Naples, Italy
• Lahore, Pakistan
• Manila, Philippines
• Odesa, Ukraine
• Exeter, United Kingdom

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

* INCLUSION CRITERIA:

To be eligible, the following inclusion criteria must be met, where applicable;

1. Participant must be four years of age or older.
2. Participant must understand and sign the protocol s informed consent document.
3. Individuals or family members of individuals with inherited eye diseases, either congenital, childhood, or age related.
4. All participants must be able to cooperate with study examination and phlebotomy.

EXCLUSION CRITERIA:

A participant is not eligible if any of the following exclusion criteria are present:

1. Participant has a disease, infection, or trauma that mimics inherited cataracts, retinal degenerations, glaucoma, etc.
2. Participant has a significant active infection (an infection requiring treatment as determined by the investigator) or a history of chronic or recurrent infections.
3. Participant requires sedation for study purposes.